InvestSMART

LTR Pharma Ltd (ASX:LTP)

ALERT: Price-sensitive ASX Announcement for LTP
Current share price for LTP : $0.490 -0.005 (-1.01%)+
Announcement
Release
17 Jul 2026 8:48AM
Price at Release
$0.495
Full Release
download
Summary
LTR Pharma Limited has executed a definitive U.S. Commercial Agreement with Shed Holdings LLC, a leading direct-to-consumer telehealth platform in the U.S., to commercialize its product ROXUS. This agreement marks a significant milestone in LTR Pharma’s strategy for U.S. market entry by leveraging Shed's established telehealth infrastructure, patient acquisition engine, and digital marketing capabilities. Shed has committed to delivering at least 150,000 units of ROXUS in the first year following the commercial launch, which is part of a framework supporting Shed's exclusivity. The agreement provides LTR Pharma a scalable entry into the U.S. market without significant time and capital investment in infrastructure. The companies are focused on completing the remaining steps required for the commercial launch, with preparations already underway, including featuring ROXUS on the Mavrox platform and establishing a patient waitlist.
Key Points
  • LTR Pharma executes definitive U.S. Commercial Agreement with Shed.
  • The agreement converts a binding Term Sheet into a comprehensive commercial agreement.
  • Plans to use Shed's telehealth platform Mavrox for ROXUS commercialization.
  • Shed commits to a minimum of 150,000 ROXUS units in the first year.
  • The agreement significantly advances LTR Pharma’s U.S. commercial strategy.
  • Strategic partnership allows access to U.S. market with minimal infrastructure investment.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should refer to the full announcement here for further information.